The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.00
Bid: 1.90
Ask: 2.10
Change: 0.10 (5.26%)
Spread: 0.20 (10.526%)
Open: 1.90
High: 2.00
Low: 1.95
Prev. Close: 1.90
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Business Update and U.S. Q2 2023 Highlights

20 Jul 2023 07:00

RNS Number : 5804G
Shield Therapeutics PLC
20 July 2023
 

 

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

 

Business Update and U.S. Q2 2023 Highlights

 

Strong Q2 2023 with U.S. Accrufer® Prescription Growth

Total U.S. prescriptions increased by 50% in 2nd quarter to 15,800, including 30% growth in June

Completion of commercial expansion to 100 sales representatives, refreshed brand positioning and marketing campaign launched in May

 

London, UK, 20 July, 2023:  Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated specialty pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency (with or without anemia) reports a business update covering recent developments, including strong Q2 2023 U.S. Accrufer® growth.

The Company saw strong prescription growth in Q2 and 1H 2023. Total prescriptions for the 2nd quarter of 2023 increased to over 15,800, a 50% increase compared to Q1 2023, and a 173% rise compared to the same period in 2022. In the first half of 2023, total prescriptions grew to approximately 26,300 which exceeds the total prescription volume for all of 2022 and represents an increase of 210% compared to 1H 2022.

The substantial growth in H1 puts Shield on track to meet its 2023 Goal for U.S. Accrufer® prescriptions:

Snapshot of increasing Q2 KPI metrics - (all comparisons are sequential to Q1 2023)

· Increase in total prescriptions -- Over 15,800, grew 50%

May grew 28% vs April, and June grew 30% vs May

· Increase in new prescriptions - grew 63%

· Increase in first time writers - grew 157%

· Positive clinical experiences leading to follow-up prescriptions

High percentage of repeat writers - 73% of the HCP's who wrote an Rx in Q1 '23 wrote another prescription in Q2

 

Substantial market opportunity: As the first and only FDA approved oral iron to treat ID/IDA with a broad label, Accrufer® has the potential to meet an important unmet medical need for both physicians and patients.

 

Key drivers in making Accrufer® the oral iron treatment of choice in the U.S. include:

· Shield/Viatris commercial expansion, completed in May - Build-out of the expanded, launch-savvy 100-person combined sales team (50/50 Shield and Viatris), was completed according to plan in May. The new, combined sales team is well-positioned to target the 12,000+ highest US prescribers.

· Refreshed branding and new marketing campaign for patients and prescribers - Shield launched its new, innovative "Ironic" campaign in May, focused on taking the "irony out of oral iron" with refreshed branding for patients and prescribers. Feedback from the field on this new approach has been very positive.

· New Chief Commercial Officer: Andy Hurley, hired in April provides dedicated leadership and expertise to lead the newly expanded commercial team to build the Accrufer® brand and deliver further success for Shield.

Shield Chief Executive Officer Greg Madison commented: "I am pleased to report that Shield's commercial growth strategy for Accrufer®/Ferracru® is continuing to deliver encouraging results, even at this early stage, as evidenced by progress across each of our key performance indicators for the first half of 2023. We've achieved this through excellent collaboration with our partner Viatris - completing our commercial expansion, refreshing the brand positioning and launching a bold, new innovative marketing campaign, and increasing our presence at medical conferences. Looking ahead, the growth in Accrufer® prescriptions seen in the 2nd quarter provides further reason for optimism in the second half of the year, as the still relatively new teams hit full stride. We continue to believe there is a very substantial market opportunity for Accrufer® and we are looking to identify ways to maximise the momentum we are building in order to further drive continued Accrufer® growth."

Cash and Balance Sheet Items

· Cash on hand of US$13.6 million (unaudited) at 30 June 2023, excluding receipt of shared marketing costs for Q2 2023 from co-commercialization partner Viatris. Cash burn is in line with management expectations, and cash on hand is sufficient to fund operations to cash flow positive by end of 2024 based on internal estimates.

· AOP debt-to-equity conversion of US$9.5 million in the period reduced remaining loan balance to US$5.5 million at 30 June 2023, which is non-interest bearing for the remainder of 2023.

 

 

For further information please contact:

 

Shield Therapeutics plc

www.shieldtherapeutics.com

Greg Madison, CEO

+44 (0) 191 511 8500

Hans-Peter Rudolf, CFO

 

Nominated Adviser and Joint Broker

Peel Hunt LLP

James Steel/Patrick Birkholm

+44 (0)20 7418 8900

 

Joint Broker

finnCap Ltd

Geoff Nash/ George Dollemore/Alice Lane/Nigel Birks/Harriet Ward

 

 

 

+44 (0)20 7220 0500

Financial PR & IR Advisor

Walbrook PR

Paul McManus/Lianne Applegarth/

Alice Woodings

+44 (0)20 7933 8780 or shield@walbrookpr.com

Investor Contact (US Advisor)

LifeSci Advisors, LLC

John Mullaly

 

 

+1 617 429 3548 or jmullaly@lifesciadvisors.com

 

About Iron Deficiency and Accrufer®/Feraccru®

Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, Accrufer® has the potential to meet an important unmet medical need for both physicians and patients.

Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA. Accrufer®/Feraccru® has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: www.accrufer.com and www.feraccru.com.

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company launched Accrufer® in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company licensed the rights to four specialty pharmaceutical companies. Feraccru® is commercialized in the UK and European Union by Norgine B.V. (Norgine), which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer®/ Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea (Korea Pharma), and with KYE Pharmaceuticals Inc. for Canada.

 

Accrufer®/Feraccru® has patent coverage until the mid-2030s.

Accrufer®/Feraccru® are registered trademarks of Shield Therapeutics.

 

Forward-Looking Statements

This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations and include statements related to the commercial strategy for Accrufer®/Feraccru®. These statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties, many of which are beyond our control, that may cause actual results and performance or achievements to be materially different from management's expectations expressed or implied by the forward-looking statements, including, but not limited to, risks associated with the Company's business and results of operations, competition and other market factors. The forward-looking statements made in this press release represent management's expectations as of the date of this press release, and except as required by law, the Company disclaims any obligation to update any forward-looking statements contained in this release, even if subsequent events cause its views to change.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSFWFAUEDSEIW
Date   Source Headline
25th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
24th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
23rd May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
22nd May 20231:25 pmRNSForm 8.3 - Shield Therapeutics PLC
19th May 20234:17 pmRNSForm 8.3 - Shield Therapeutics Plc
19th May 20232:29 pmRNSForm 8.3 – Shield Therapeutics plc
19th May 20237:00 amRNS2022 Annual Report and 2023 AGM Notice
18th May 20233:15 pmRNSForm 8 (OPD) - Shield Therapeutics plc
18th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
17th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
17th May 20237:15 amEQSHardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q’23 Accrufer prescriptions
16th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
12th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
11th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
10th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
9th May 20235:20 pmRNSForm 8 (OPD) - Shield Therapeutics plc
9th May 20234:00 pmRNSRule 2.9 Announcement and TVR Update
9th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
9th May 202311:04 amGNWForm 8.3 - Shield Therapeutics plc
5th May 20233:09 pmRNSForm 8 (DD) - Shield Therapeutics Plc
5th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
5th May 202311:55 amRNSForm 8.3 - SHIELD THERAPEUTICS PLC
4th May 20232:40 pmRNSAOP Loan Conversion and Mandatory Cash Offer
27th Apr 20237:00 amRNSBusiness Update and Unaudited Results
12th Apr 20237:00 amRNSNotice of Results
5th Apr 20237:00 amRNSAppointment of Chief Commercial Officer
31st Mar 20237:00 amRNSBlock Listing 6 Monthly Return
15th Mar 20234:35 pmRNSPrice Monitoring Extension
28th Feb 20237:00 amRNSTotal Voting Rights Update
17th Feb 202311:05 amRNSSecond Price Monitoring Extn
17th Feb 202311:00 amRNSPrice Monitoring Extension
9th Feb 20234:40 pmRNSSecond Price Monitoring Extn
9th Feb 20234:35 pmRNSPrice Monitoring Extension
9th Feb 20239:05 amRNSSecond Price Monitoring Extn
9th Feb 20239:00 amRNSPrice Monitoring Extension
9th Feb 20237:00 amRNSFull Year Trading Update
23rd Jan 202311:15 amEQSHardman & Co Q&A on Shield Therapeutics (STX): Positioned for profitability with Viatris deal and its additional capital
13th Jan 202310:30 amRNSHolding(s) in Company
13th Jan 20237:16 amEQSHardman & Co Research: Shield Therapeutics (STX) - Positioned for growth and profitability
12th Jan 20232:40 pmRNSHolding(s) in Company
12th Jan 20232:15 pmRNSHolding(s) in Company
9th Jan 20235:10 pmRNSPartial AOP Loan Conversion
9th Jan 20233:56 pmRNSHolding(s) in Company
9th Jan 20233:25 pmRNSHolding(s) in Company
5th Jan 20233:45 pmRNSResult of General Meeting & Open Offer
28th Dec 20227:00 amRNSTotal Voting Rights Update
28th Dec 20227:00 amRNSPDMR Transaction Notification
16th Dec 20227:00 amRNSPublication of Circular &Notice of General Meeting
13th Dec 20223:45 pmRNSSuccessful completion of US$18.5m Equity Fundraise
13th Dec 20227:02 amRNSInvestor presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.